Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1024)	6/10/2003 3:45:28 PM
From: Jibacoa	Respond to of 7424

VPHM Is up 15% with volume over 1.235M (more than 2x its daily average.) No news since they released their Year-end results a few days ago. siliconinvestor.com Bernard

To: Jibacoa who wrote (1024)	6/11/2003 3:22:34 AM
From: Henrik	Respond to of 7424

The PGL(AF) firework continued on the ASX in Australia following the lift on Nasdaq. Progen maintained the momentum to the close on ASX in Australia. Closed at HOD - up 49.4% with good volume for this stock. Looks like the Sydney-siders attending the presentation in Sydney this afternoon kicked the price up another few cents just before the close. Let's see what tonight will bring on Nasdaq and then another presentation in Melbourne tomorrow morning (OZ time). From the presentation it appears that Progen's PI-88 trials are advancing well and more data should become available as the trials continue. Also, the company recently hired Dr. Darren Schliebs, Ph.D. as Vice President Business Development. In this position he will be working on licensing agreements with major pharmaceutical companies. The company expects to enter into such agreements in the foreseeable future. Still some way to go on the drug side, but licensing agreement(s) will greatly change the company's financial position with up-front and milestone payments and also provide a good deal of additional R&D cash. About Darren Schliebs. Dr. Darren Schliebs, Ph.D. joined us in May 2003 as Vice President for Business Development. Dr. Schliebs brings international business development experiences coupled to a strong background in scientific research and biotechnology. Prior to joining Progen Dr. Schliebs was Business Development Manager for Australian biotech Alchemia Pty. Ltd., and was located in the San Francisco Bay Area in the United States. Dr. Schliebs was with Alchemia from 1998 to 2003, the last 3 years of which was spent in the U.S. This was preceded in 1997 by a Research position at The Australian National University, and earlier Doctoral studies at The University of Adelaide and The Australian National University, along with a stint at Loughborough University in the U.K. Dr. Schliebs has published several articles in scientific journals, a patent and has authored articles in science magazines. Dr. Schliebs holds a B.Sc. with first class honours in Organic Chemistry from the University of Adelaide and a Ph.D. in Chemistry from The Australian National University. progen.com.au